Recommended Dosing for Pemetrexed and Docetaxel
For pemetrexed, administer 500 mg/m² intravenously every 3 weeks with mandatory vitamin supplementation (folic acid 350-1,000 mcg daily and vitamin B12 1,000 mcg intramuscularly every 9 weeks, starting 1-2 weeks before treatment). For docetaxel, administer 75 mg/m² intravenously over 1 hour every 3 weeks as the standard dose. 1, 2
Pemetrexed Dosing Details
The standard dose of 500 mg/m² every 3 weeks is firmly established across multiple guidelines and FDA labeling 1. This dosing applies specifically to:
- Second-line therapy for recurrent/progressive NSCLC (non-squamous histology only)
- Patients with adequate performance status (0-2)
Critical Supplementation Requirements
Vitamin supplementation is non-negotiable to prevent severe toxicity 1:
- Folic acid: 350-1,000 mcg orally daily
- Vitamin B12: 1,000 mcg intramuscularly every 9 weeks
- Timing: Begin 1-2 weeks before first dose and continue until 3 weeks after last dose
Premedication for Rash Prevention
Administer dexamethasone 2 mg daily for 5 days starting the day after pemetrexed (days 2-6) to prevent rash, which is more effective and better tolerated than the traditional 3-day higher-dose regimen 3.
Docetaxel Dosing Details
Standard Dosing
75 mg/m² intravenously over 1 hour every 3 weeks is the recommended dose for second-line NSCLC after platinum-based chemotherapy failure 1, 2.
Critical Safety Warning
Never use 100 mg/m² in previously treated patients - this dose is associated with significantly increased hematologic toxicity, infections, and treatment-related mortality 2.
Dose-Reduced Schedule for High-Risk Patients
For patients at high risk of hematologic toxicity or with prior febrile neutropenia, use 33.3-40 mg/m² administered either:
- Weekly for 6 weeks on an 8-week cycle, OR
- Weekly for 3 weeks on a 4-week cycle 1
Mandatory Premedication
All patients must receive dexamethasone 16 mg/day (8 mg twice daily) for 3 days starting 1 day before docetaxel to reduce fluid retention and hypersensitivity reactions 2.
Key Clinical Considerations
Histology Matters
Pemetrexed is restricted to non-squamous NSCLC only - do not use in squamous cell carcinoma 4, 5. Docetaxel can be used regardless of histology.
Comparative Efficacy
Both agents demonstrate equivalent survival outcomes when used as second-line therapy. Pemetrexed offers significantly fewer side effects, particularly less neutropenia (5.3% vs 40.2% grade 3/4), febrile neutropenia (1.9% vs 12.7%), and alopecia (6.4% vs 37.7%) compared to docetaxel 6.
Administration Schedule
The standard every 3 weeks (q3w) schedule is evidence-based for both agents. While alternate dosing (q4 weeks) for pemetrexed has been explored and appears feasible without detriment to survival 7, the q3w schedule remains the standard recommendation.
Combination Warning
Do not combine pemetrexed and docetaxel - this combination results in severe toxicity including grade 3 fatigue, stomatitis, diarrhea, and febrile neutropenia without improved efficacy 8, 9.